Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20137 in Moderate-to-severe Plaque Psoriasis
NCT06844799Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of QX004N in plaque psoriasis, sponsored by Hansoh Pharmaceutical Group. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
QX004N
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06844799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06844799.